^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

PBF-1129

i
Other names: PBF-1129, PBF 1129, PBF1129
Associations
Company:
Palobiofarma, Xoma
Drug class:
Adenosine A2B receptor antagonist
Associations
8ms
Enrollment open • Metastases
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • STK11 (Serine/threonine kinase 11)
|
Opdivo (nivolumab) • PBF-1129
9ms
Trial suspension • Metastases
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • STK11 (Serine/threonine kinase 11)
|
Opdivo (nivolumab) • PBF-1129
9ms
PBF-1129 in Patients With NSCLC (clinicaltrials.gov)
P1, N=18, Active, not recruiting, Palobiofarma SL | Trial completion date: Dec 2023 --> Aug 2024 | Trial primary completion date: Oct 2023 --> May 2024
Trial completion date • Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ALK mutation • ROS1 mutation
|
PBF-1129
over1year
Improving combination therapies: Targeting A2B adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression. (PubMed, J Natl Cancer Inst)
Data identify A2BAR as a valuable therapeutic target to modify metabolic and immune TME to reduce immunosuppression, enhance the efficacy of immunotherapies, and support clinical application of PBF-1129 in combination therapies.
Journal • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • IFNG (Interferon, gamma)
|
PBF-1129
almost2years
PBF-1129 in Patients With NSCLC (clinicaltrials.gov)
P1, N=18, Active, not recruiting, Palobiofarma SL | Recruiting --> Active, not recruiting | Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Oct 2023
Enrollment closed • Trial completion date • Trial primary completion date • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ALK mutation • ROS1 mutation
|
PBF-1129
2years
Enrollment open • Metastases
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
Opdivo (nivolumab) • PBF-1129
2years
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=30, Not yet recruiting, Dwight Owen | Initiation date: Apr 2022 --> Nov 2022
Trial initiation date • Metastases
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
Opdivo (nivolumab) • PBF-1129
over2years
New P1 trial
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
Opdivo (nivolumab) • PBF-1129
4years
PBF-1129 in Patients With NSCLC (clinicaltrials.gov)
P1, N=18, Recruiting, Palobiofarma SL | Trial completion date: Dec 2019 --> Jun 2023 | Trial primary completion date: Nov 2019 --> Dec 2022
Clinical • Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ALK mutation • ROS1 mutation
|
PBF-1129